

## NEWS RELEASE

### **RONNIE MILLER APPOINTED NEW CHAIRMAN, RX&D BOARD OF DIRECTORS**

**Montreal, November 14, 2007** – *Canada's Research-Based Pharmaceutical Companies (Rx&D)* is pleased to announce the appointment of Ronnie Miller, President and Chief Executive Officer (CEO) of Hoffmann-La Roche Limited (Roche Canada) as Chairman of the association's Board of Directors. Mr. Miller assumed the Board leadership at today's Rx&D Annual General meeting held in Montreal.

Mr. Miller is a member of Rx&D's Executive Committee and Board of Directors. Until becoming Board Chairman, he served on several industry committees including Public Affairs, Stakeholder Relations and, more recently, as Chair of the Rx&D Federal Affairs/FPT Relations Standing Committee.

"It is my privilege to serve as Chair of Rx&D's Board of Directors at a time in our industry where we are truly at a crossroads", said Mr. Miller. "Now, more than ever, we must galvanize the voice of the life-sciences sector to break down the barriers preventing physicians from accessing innovation and putting patients at the centre of all health-care decisions in this country."

Mr. Miller has over 28 years of extensive and varied experience in the pharmaceutical industry. He began his career in the United Kingdom as a sales representative and held a series of progressive positions including Sales Management, Product Management, Business Unit Director, and National Sales Manager.

In 1988, Mr. Miller joined Roche as National Sales Manager for Roche Products Ltd. in the United Kingdom. In 1992, he moved to Roche's head office in Basel, Switzerland, as the International Product Manager for Neupogen®.

From 1993-1996, he worked for Roche in Japan as Marketing Director and Deputy Divisional Director of the Pharmaceutical Division. In 1996, he moved back to Roche's global head office in Basel, to lead the global task force for Xenical®. Mr. Miller returned to the United Kingdom in 1997 as Divisional Director of Pharmaceuticals and remained there until April 2000, when he was appointed to his current position as President and CEO, Roche Canada.

*Canada's Research-Based Pharmaceutical Companies (Rx&D)* is an association of members dedicated to improving the health of all Canadians. As a partner of the health-care system, our discoveries help eliminate the need for medical procedures, such as surgery, which have a significant impact on patient quality of life and health-care budgets. Our community represents over 22,000 men and women working for more than 50 member companies in Canada and is responsible for generating 100,000 jobs across Canada.

- 30 -

For further information:

François Lessard  
Communications  
Tel: 613-236-0455